Cargando…

Case fatality rate of COVID-19: a systematic review and meta-analysis

OBJECTIVE: The ongoing novel coronavirus disease 2019 (COVID-19) is the leading cause of morbidity and mortality due to its contagious nature and absence of vaccine and treatment. Although numerous primary studies reported extremely variable case fatality rate (CFR) of COVID-19, no review study atte...

Descripción completa

Detalles Bibliográficos
Autores principales: ALIMOHAMADI, YOUSEF, TOLA, HABTEYES HAILU, ABBASI-GHAHRAMANLOO, ABBAS, JANANI, MAJID, SEPANDI, MOJTABA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pacini Editore Srl 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451339/
https://www.ncbi.nlm.nih.gov/pubmed/34604571
http://dx.doi.org/10.15167/2421-4248/jpmh2021.62.2.1627
_version_ 1784569822625923072
author ALIMOHAMADI, YOUSEF
TOLA, HABTEYES HAILU
ABBASI-GHAHRAMANLOO, ABBAS
JANANI, MAJID
SEPANDI, MOJTABA
author_facet ALIMOHAMADI, YOUSEF
TOLA, HABTEYES HAILU
ABBASI-GHAHRAMANLOO, ABBAS
JANANI, MAJID
SEPANDI, MOJTABA
author_sort ALIMOHAMADI, YOUSEF
collection PubMed
description OBJECTIVE: The ongoing novel coronavirus disease 2019 (COVID-19) is the leading cause of morbidity and mortality due to its contagious nature and absence of vaccine and treatment. Although numerous primary studies reported extremely variable case fatality rate (CFR) of COVID-19, no review study attempted to estimate the CFR of COVID-19. The current systematic review and meta-analysis were aimed to assess the pooled CFR of COVID-19. METHODS: Electronic databases: PubMed, Science Direct, Scopus, and Google Scholar were searched to retrieve the eligible primary studies that reported CFR of COVID-19. Keywords: (“COVID-19”OR “COVID-2019” OR “severe acute respiratory syndrome coronavirus 2”OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-2” OR “2019nCoV” OR ((“Wuhan” AND (“coronavirus” OR “coronavirus”)) AND (2019/12[PDAT] OR 2020[PDAT]))) AND (“mortality “OR “mortality” OR (“case” AND “fatality” AND “rate”) OR “case fatality rate”) were used as free text and MeSH term in searching process. A random-effects model was used to estimate the CFR in this study. I(2) statistics, Cochran’s Q test, and T(2) were used to assess the functional heterogeneity between included studies. RESULTS: The overall pooled CFR of COVID 19 was 10.0%(95% CI: 8.0-11.0); P < 0.001; I(2) = 99.7). The pooled CFR of COVID-19 in general population was 1.0% (95% CI: 1.0-3.0); P < 0.001; I(2) = 94.3), while in hospitalized patients was 13.0% (95% CI: 9.0-17.0); P < 0.001, I(2) = 95.6). The pooled CFR in patients admitted in intensive care unit (ICU) was 37.0% (95% CI: 24.0-51.0); P < 0.001, I(2) = 97.8) and in patients older than 50 years was 19.0% (95% CI: 13.0-24.0); P < 0.001; I(2) = 99.8). CONCLUSION: The present review results highlighted the need for transparency in testing and reporting policies and denominators used in CFR estimation. It is also necessary to report the case’s age, sex, and the comorbidity distribution of all patients, which essential in comparing the CFR among different segments of the population.
format Online
Article
Text
id pubmed-8451339
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Pacini Editore Srl
record_format MEDLINE/PubMed
spelling pubmed-84513392021-10-01 Case fatality rate of COVID-19: a systematic review and meta-analysis ALIMOHAMADI, YOUSEF TOLA, HABTEYES HAILU ABBASI-GHAHRAMANLOO, ABBAS JANANI, MAJID SEPANDI, MOJTABA J Prev Med Hyg Review OBJECTIVE: The ongoing novel coronavirus disease 2019 (COVID-19) is the leading cause of morbidity and mortality due to its contagious nature and absence of vaccine and treatment. Although numerous primary studies reported extremely variable case fatality rate (CFR) of COVID-19, no review study attempted to estimate the CFR of COVID-19. The current systematic review and meta-analysis were aimed to assess the pooled CFR of COVID-19. METHODS: Electronic databases: PubMed, Science Direct, Scopus, and Google Scholar were searched to retrieve the eligible primary studies that reported CFR of COVID-19. Keywords: (“COVID-19”OR “COVID-2019” OR “severe acute respiratory syndrome coronavirus 2”OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-2” OR “2019nCoV” OR ((“Wuhan” AND (“coronavirus” OR “coronavirus”)) AND (2019/12[PDAT] OR 2020[PDAT]))) AND (“mortality “OR “mortality” OR (“case” AND “fatality” AND “rate”) OR “case fatality rate”) were used as free text and MeSH term in searching process. A random-effects model was used to estimate the CFR in this study. I(2) statistics, Cochran’s Q test, and T(2) were used to assess the functional heterogeneity between included studies. RESULTS: The overall pooled CFR of COVID 19 was 10.0%(95% CI: 8.0-11.0); P < 0.001; I(2) = 99.7). The pooled CFR of COVID-19 in general population was 1.0% (95% CI: 1.0-3.0); P < 0.001; I(2) = 94.3), while in hospitalized patients was 13.0% (95% CI: 9.0-17.0); P < 0.001, I(2) = 95.6). The pooled CFR in patients admitted in intensive care unit (ICU) was 37.0% (95% CI: 24.0-51.0); P < 0.001, I(2) = 97.8) and in patients older than 50 years was 19.0% (95% CI: 13.0-24.0); P < 0.001; I(2) = 99.8). CONCLUSION: The present review results highlighted the need for transparency in testing and reporting policies and denominators used in CFR estimation. It is also necessary to report the case’s age, sex, and the comorbidity distribution of all patients, which essential in comparing the CFR among different segments of the population. Pacini Editore Srl 2021-07-30 /pmc/articles/PMC8451339/ /pubmed/34604571 http://dx.doi.org/10.15167/2421-4248/jpmh2021.62.2.1627 Text en ©2021 Pacini Editore SRL, Pisa, Italy https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International) license. The article can be used by giving appropriate credit and mentioning the license, but only for non-commercial purposes and only in the original version. For further information: https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en
spellingShingle Review
ALIMOHAMADI, YOUSEF
TOLA, HABTEYES HAILU
ABBASI-GHAHRAMANLOO, ABBAS
JANANI, MAJID
SEPANDI, MOJTABA
Case fatality rate of COVID-19: a systematic review and meta-analysis
title Case fatality rate of COVID-19: a systematic review and meta-analysis
title_full Case fatality rate of COVID-19: a systematic review and meta-analysis
title_fullStr Case fatality rate of COVID-19: a systematic review and meta-analysis
title_full_unstemmed Case fatality rate of COVID-19: a systematic review and meta-analysis
title_short Case fatality rate of COVID-19: a systematic review and meta-analysis
title_sort case fatality rate of covid-19: a systematic review and meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451339/
https://www.ncbi.nlm.nih.gov/pubmed/34604571
http://dx.doi.org/10.15167/2421-4248/jpmh2021.62.2.1627
work_keys_str_mv AT alimohamadiyousef casefatalityrateofcovid19asystematicreviewandmetaanalysis
AT tolahabteyeshailu casefatalityrateofcovid19asystematicreviewandmetaanalysis
AT abbasighahramanlooabbas casefatalityrateofcovid19asystematicreviewandmetaanalysis
AT jananimajid casefatalityrateofcovid19asystematicreviewandmetaanalysis
AT sepandimojtaba casefatalityrateofcovid19asystematicreviewandmetaanalysis